Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 9Terminated 5Recruiting 5Active not recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 3Genitourinary 2Breast 2Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Gastrointestinal 1CNS 1

Conditions

Breast Neoplasms 849Triple Negative Breast Neoplasms 136Ovarian Neoplasms 55Colorectal Neoplasms 49Carcinoma, Non-Small-Cell Lung 47Neoplasms 43Neoplasm Metastasis 43Prostatic Neoplasms 42Lung Neoplasms 38Melanoma 30Carcinoma, Intraductal, Noninfiltrating 29Uterine Cervical Neoplasms 27Pancreatic Neoplasms 25Colonic Neoplasms 25Stomach Neoplasms 23Squamous Cell Carcinoma of Head and Neck 23Endometrial Neoplasms 23Carcinoma, Renal Cell 23Breast Carcinoma In Situ 22Esophageal Neoplasms 17Urinary Bladder Neoplasms 16Motor Activity 16Inflammatory Breast Neoplasms 16Head and Neck Neoplasms 16Small Cell Lung Carcinoma 15Sarcoma 14Breast Cancer Female 13Brain Neoplasms 12Anatomic Stage I Breast Cancer AJCC v8 12Gastrointestinal Neoplasms 11

Interventions

liposomal doxorubicin 1Taxes 1Paclitaxel 1Lomustine 1Irinotecan 1Gemcitabine 1Doxorubicin 1Carboplatin 1Albumin-Bound Paclitaxel 13-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 111-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Hereditary Sensory and Autonomic Neuropathies × Breast × Clear all
NCT03678883 2026-04-03

9-ING-41 in Patients With Advanced Cancers

Actuate Therapeutics Inc.

Phase 2 Active not recruiting
350 enrolled
BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT04520269 2025-09-25

A Single Arm, Phase Ib/II Trial of Single Agent Pacritinib in Patients With 1q21.3 Amplified Solid Tumors Enriching for Interleukin-1 Receptor-associated Kinase 1 Pathway Activation (PAIR)

National University Hospital, Singapore

Phase 1/2 Active not recruiting
74 enrolled
Breast

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡